Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus TESTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus TESTIM.
DEPO-TESTOSTERONE vs TESTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Testosterone replacement therapy; binds to and activates androgen receptors, modulating gene expression leading to male sexual development and maintenance of secondary sexual characteristics.
50-400 mg IM every 2-4 weeks
Apply 5 g (1 tube) of 1% gel to clean, dry, intact skin of the shoulders, upper arms, or abdomen once daily, preferably in the morning. Dosage may be adjusted to 10 g (2 tubes) depending on clinical response. Apply immediately after opening and avoid bathing or swimming for at least 30 minutes.
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Terminal elimination half-life of testosterone from serum is approximately 10-100 minutes after intravenous administration, but after transdermal application of Testim, the apparent half-life is longer (around 1-2 hours) due to continued absorption from the skin depot. The half-life of active metabolites (e.g., dihydrotestosterone) is about 2-3 hours.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Category D/X
Category C
Androgen
Androgen